Biotech of the Week: Synpromics, the Scottish company enabling precise Gene Expression
This week we leave the wonderful weather of Mallorca and head North, through France, England…
This week we leave the wonderful weather of Mallorca and head North, through France, England…
UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial…
The €1.1M drug Glybera was the first gene therapy on the European market. UniQure wants…
In May, Bristol-Myers Squibb (BMS) nailed down the exclusive access to uniQure's gene therapy platform…
GlaxoSmithKline has become the first big pharma company to file a gene therapy approval case to the…
Last month, Bristol-Myers Squibb (BMS) and UniQure, the Dutch pioneer in human gene therapy, were at…
Synpromics has formed a collaboration with uniQure, the Dutch pioneer in human gene therapy, to…
Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, sold PneumRx of…
What could you buy with €1,1M euros? A house? Or a single prescription for a new…
uniQure, a leader in human gene therapy, today announced the acquisition of InoCard GmbH, an…